Advertisement
Singapore markets closed
  • Straits Times Index

    3,331.70
    +5.42 (+0.16%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • Dow

    39,112.16
    -299.05 (-0.76%)
     
  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     
  • Bitcoin USD

    61,523.83
    +476.32 (+0.78%)
     
  • CMC Crypto 200

    1,272.79
    -10.99 (-0.86%)
     
  • FTSE 100

    8,213.64
    -34.15 (-0.41%)
     
  • Gold

    2,325.10
    -5.70 (-0.24%)
     
  • Crude Oil

    81.20
    +0.37 (+0.46%)
     
  • 10-Yr Bond

    4.2830
    +0.0450 (+1.06%)
     
  • Nikkei

    39,667.07
    +493.92 (+1.26%)
     
  • Hang Seng

    18,089.93
    +17.03 (+0.09%)
     
  • FTSE Bursa Malaysia

    1,590.95
    +5.57 (+0.35%)
     
  • Jakarta Composite Index

    6,905.64
    +22.94 (+0.33%)
     
  • PSE Index

    6,313.11
    +14.06 (+0.22%)
     

Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)

Peter Garcia, Chief Financial Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), purchased 12,000 shares of the company on June 13, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 122,348 shares of the company.

ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company focused on developing therapies to improve cancer treatment. The company's shares were priced at $8.53 on the day of the transaction, resulting in a market cap of $432.431 million.

Over the past year, the insider has engaged in multiple transactions, purchasing a total of 12,000 shares and selling 887 shares. The recent acquisition by the insider is part of a broader trend observed within the company, where there have been 2 insider buys and 11 insider sells over the past year.

Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)
Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)

For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further on GuruFocus.

ADVERTISEMENT

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.